Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05791318




Registration number
NCT05791318
Ethics application status
Date submitted
16/03/2023
Date registered
30/03/2023

Titles & IDs
Public title
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
Scientific title
A Phase 1, Randomized, Triple-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Monoclonal Antibody VYD222 in Healthy Adult Participants
Secondary ID [1] 0 0
VYD222-1-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COVID-19 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VYD222
Other interventions - Placebo

Experimental: Cohort 1 - 10 total participants Cohort 1. 8 participants on VYD222 2 participants on placebo

Experimental: Cohort 2 - 10 total participants Cohort 2. 8 participants on VYD222 2 participants on placebo

Experimental: Cohort 3 - 10 total participants Cohort 3. 8 participants on VYD222 2 participants on placebo


Treatment: Drugs: VYD222
Monoclonal antibody

Other interventions: Placebo
Matching Placebo
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of TEAEs (including AEs and SAEs)
Timepoint [1] 0 0
Through 12 Months
Secondary outcome [1] 0 0
Incidence of ADAs against VYD222
Timepoint [1] 0 0
12 Months
Secondary outcome [2] 0 0
Assessment of PK Parameter: area under the concentration-time curve from time zero extrapolated to infinity for VYD222
Timepoint [2] 0 0
12 Months
Secondary outcome [3] 0 0
Assessment of PK Parameter: area under the concentration-time curve from time zero to the last measurable concentration for VYD222
Timepoint [3] 0 0
12 Months
Secondary outcome [4] 0 0
Assessment of PK Parameter: area under the concentration-time curve from time zero to t for VYD222
Timepoint [4] 0 0
12 Months
Secondary outcome [5] 0 0
Assessment of PK Parameter: Cmax (maximum serum concentration)
Timepoint [5] 0 0
12 Months
Secondary outcome [6] 0 0
Assessment of PK Parameter: Tmax (time to reach maximum serum concentration)
Timepoint [6] 0 0
12 Months
Secondary outcome [7] 0 0
Assessment of PK Parameter: Clearance of VYD222
Timepoint [7] 0 0
12 Months
Secondary outcome [8] 0 0
Assessment of PK Parameter: Half-life of VYD222
Timepoint [8] 0 0
12 Months
Secondary outcome [9] 0 0
Assessment of PK Parameter: volume of distribution at steady state of VYD222
Timepoint [9] 0 0
12 Months
Secondary outcome [10] 0 0
Assessment of PK Parameter: volume of distribution during terminal phase of VYD222
Timepoint [10] 0 0
12 Months

Eligibility
Key inclusion criteria
* Has a body mass index 18.5 to 32.0 kg/m2, inclusive.
* Negative for current SARS-CoV-2 infection by rapid antigen test on Day -1.
* Is seropositive to N and/or S SARS-CoV-2 antigens at Screening.
* For participants assigned female sex at birth: Is not of childbearing potential OR is of childbearing potential and practicing highly effective contraception.
* Is able and willing to provide written informed consent.
* NOTE: Other protocol defined inclusion/exclusion criteria apply
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Intends to receive a COVID-19 vaccine/booster within 3 months of Day 1.
* Is pregnant, breastfeeding, or seeking pregnancy while on study.
* Has a history of a malignancy (or active malignancy), except for participants with basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix who have been treated and cured.
* Has had any symptoms of acute respiratory illness (e.g., cough, shortness of breath, sore throat, fatigue, loss of smell, fever), or other febrile illness within 2 weeks prior to dosing.
* Has evidence of active infection with HIV, HBV, or HCV.
* Has donated more than 500 mL of blood within 60 days before the scheduled dose of study drug.
* Had major surgery within 30 days prior to study drug dosing or planned surgeries within 12 months after planned study drug dosing.
* Received any investigational drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to Screening or planned administration of any investigational drug or biologic during the study period.
* Received immunoglobulin or blood products within 6 months prior to Screening.
* Previously received a mAb within 6 months or 5 half-lives (whichever is longer) prior to Screening.
* NOTE: Other protocol defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
8/05/2024
Sample size
Target
Accrual to date
Final
30
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Linear Clinical Research - Joondalup
Recruitment postcode(s) [1] 0 0
6027 - Joondalup

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Invivyd, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Novotech (Australia) Pty Limited
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05791318